One of the privileges of writing 2025's 40 year (intergenrational) future history in 2024, is we can diagnose why humans failed to unite around most urgent goals as well as which hypotheses The Economist (the earliest global viewspaper of Smithian free market systems) and Future Historians got wrong.
Now its true my family friend network have almost all suffered from losing family members early to cancer so yes you can examine this list of reasonings for bias
overall question 1 why isnt one of the first 2 biggest ever AI factories working on ending cancer or other diseases mainly explained by envirinmental and genetic data (the other biggest ai factiry needed to map how to remap every places acess to energy and water - where places eg island nations cant possibly be energy sufficient is there something else they can trade transparently with places with abundant acceess.
CANCER AI SEEMS SIMPLER THAN ENERGY AI. These seem to be some of the reasosn
we havent designed global media around goal heroes like end cancer only spoirts/pop heroes
neither swiss (epicenter of world health) or usa (epicenter of biggest capital alocations) models of developing drug market solutons fit data modeling chalenges which needed years of cooperation instead of 90 days compwtion ; america is just about the only nation that alows pharam to spend mots of its ad money on ask your doctor why he isnt prescribing this most expensive new fruf in the world- no narketing has even been designed to destroy affrodability the way big pharma does
At another level while the world needs transparent multilateral uniting of nations it did not need 25 years of green washing of sdgs. Ais models have never solved 10+ uear chaleengs which cancer ai most certainly was. Ultimately the locations of UN's 4 main offices dont help mediate conflicts - new york, switerland outside EU, Kenya, Thailand. Lets hope Denev world AI summiy 2027 followed by UAE AI world summit 2028 addresses some of this
at another level the nations with the greatest engineerting capacity are not collaborating around the most human solution needs; oo i know this sounds unrea;listic in 2026 but 2 things needed to happen arpund 1999 to vcelebrate new millennium - a worldwide reality tv program which debated goals just as interactive influencers started to take over impacts from mass media - see chpater 6 of 2025 reportrt. a G2 needed to be formed bu usa and china - and what it agreed or disagreed on needed to ne transparently published each year so rest og world's 80 per cnet of humans could chat
Baxk to cancer star with those over 70 - japans new frontiers chnel at nhk world is a kalodoscope of non agressive soliution 70 year old bodies most need to live with camcer. We need all public broadcatsers to come together around such chanels.
Teacher training hospotls need to come together around funding mopdels whoch do not siloose the tech genius from the practicce genius from everyone elses understanding. Roadology got this roght for 10 years from 2003 to 2012 as it designed progamming of piexles instead og 0,1 but it is unclear whether there is any first class medical netwirk that has spent the second decade of acelerating data pattern intelligence uniting relevant labs.
We must end acidental war of elders versus youth- half the world's brains are under 30 but currently they have less tha 5% decision power over ai investments - at least proving everyone can unite round cancer daya might give youth as much hope in next decade as space race gave my fgeneration og youth in 1960s- matjematicains saw this hope as being satellites would end cost of distance of data clouds exchnaging every communities most urgent data and need for ai layer 5 apps gor action
Countries that only have commercial media destroy transformation of education aeounbd communities. 8/28 yesterday at a brave dialogue on why cant usa and brazil hel each other on ever one urgent mmutiual need a presenter from ameruca enterprise institute provided wonderful daya on curricula america now needs if community layer 5 ai isto become a rising thing - great if anyone concerened with education tranformation checks it our
https://connect.aei.org/4755635
------
at another level -its quite easy to map where biggest vera robin factiriuies are being builr bt platform around nvidia and taiwan - so is anyone helping nvidi free just a little og its capital to 10 year dfata prohects or are we leaving everything to family foundations
at 8.26 wall street call hjensen mentioned 42% of current sales dpeend on what mazin meta and microsft choose toai factiry but over next 2 years ai robotc agents will need transnational investment and the world should mediate what layer 3 ai data sovereignty of places connect with machines whose maths brain power is billion times more than separate human minds - more at http://neumann.ning.com
does nviffa or jrnsen huang family fund any cancer ai Thought for 17s Yes, both NVIDIA (the company and its former foundation programs) and the Jensen/Lori Huang family foundation have supported cancer-related research, including computational/AI approaches, though the family foundation’s public giving is broader and less specifically labeled “cancer AI.” insidephilanthropy.com NVIDIA / NVIDIA Foundation Compute the Cure (roughly 2011–2017): The NVIDIA Foundation ran this philanthropic initiative and awarded grants (typically ~$100k–$200k each, totaling more than $5 million overall) for projects using GPU/parallel computing, deep learning, and computational methods for cancer research, diagnostics, genomics, mutation detection, drug discovery tools, and related work. Recipients included teams at the University of Toronto, Stanford, Dana-Farber, Ludwig Institute, TGen, and others. The program was later discontinued as the foundation shifted focus. nvidia.com Ongoing company-level support: NVIDIA is a backer of the Cancer AI Alliance (CAIA, launched ~2024), which partners major cancer centers (Dana-Farber, Fred Hutch, Memorial Sloan Kettering, Johns Hopkins/Sidney Kimmel) with tech firms (including NVIDIA, AWS, Microsoft, and others). It provides funding, compute, and expertise for AI-driven cancer research. NVIDIA also has broader AI-for-biology/drug-discovery efforts (e.g., collaborations involving large compute investments) that apply to oncology. siliconangle.com Jen-Hsun & Lori Huang Foundation (family foundation) Cancer research: In 2008 it gave $5 million to build a laboratory for cancer research (linked to Oregon Health & Science University / Oregon State University connections). insidephilanthropy.com AI / biomedical / computing: The foundation supports higher education, public health, STEM, and AI-related work. Notable examples include backing for AI4ALL (diversity in AI) and large gifts for AI-powered research infrastructure (e.g., Oregon State University’s Collaborative Innovation Complex with an NVIDIA-powered supercomputer supporting various scientific fields; and reported support for UCSF biomedical research accelerated by AI and advanced computing). It has also donated substantial GPU compute resources (over $100 million via CoreWeave) for open science and AI research at universities and nonprofits. observer.com The foundation is low-profile (no public website, limited transparency; much giving historically routed through donor-advised funds). Publicly disclosed grants emphasize universities (especially Oregon State and Stanford), public health, STEM/AI, and Bay Area causes rather than narrowly branded “cancer AI” programs. Its stated priorities include higher education, public health, and STEM initiatives. Note: An early NVIDIA employee (not the Huang family) separately donated $20 million to Mayo Clinic specifically for AI innovation in cancer. NVIDIA’s commercial AI platforms and partnerships are widely used in cancer research, but that is distinct from direct philanthropic funding by the family foundation. In short, NVIDIA has a clearer historical and current track record of supporting computational/AI cancer research, while the Huang family foundation has funded cancer research infrastructure and AI/biomedical computing that can support cancer AI work, alongside broader education and public-health priorities. Explore Cancer AI Alliance partners Investigate NVIDIA Clara healthcare platform can you check sny deep cancer segments in asia eg nvidia japan elderly or as key to its twin desugn of medical colleges out iof hongkong and taiwan Thought for 28s Yes, there are active NVIDIA-supported cancer AI and broader medical AI efforts in Asia (especially Japan and Taiwan), driven in part by aging populations and healthcare needs. No clear evidence links NVIDIA as a key element to any specific “twin design of medical colleges” project originating from or connecting Hong Kong and Taiwan. Japan (strong elderly/healthcare focus + cancer AI) Japan’s population is ~30% aged 65+, creating pressure for AI to address clinician shortages and improve care. NVIDIA supports “sovereign AI” healthcare initiatives using platforms like Tokyo-1 (DGX supercomputer), BioNeMo (drug discovery), MONAI (medical imaging), Parabricks (genomics), and Holoscan (robotics/imaging). blogs.nvidia.com Key cancer-related segments: Genomics/cancer research: University of Tokyo Human Genome Center (and government whole-genome projects focused on cancer) uses NVIDIA Parabricks for accelerated DNA/RNA analysis. Imaging & early detection: Osaka University + NVIDIA Japan developed Mucosight AI (oral mucosa image analysis for early oral cancer detection), which received Japanese regulatory approval (Ministry of Health). Other work includes AI for gastrointestinal cancers, radiation therapy planning (e.g., Ai-Seg organ segmentation), and CT systems (Canon photon-counting CT; Fujifilm AI-augmented screening centers for cancer/chronic disease with lower radiation). Drug discovery & models: Japanese pharma (Astellas, Daiichi Sankyo, Ono, Eisai) use BioNeMo/Tokyo-1. Biomy is building virtual cell foundation models with data from the Japanese Foundation for Cancer Research. Robotics/surgery: Applications for real-time organ detection, surgical support, and eldercare robots (e.g., Kawasaki Heavy Industries plans using Holoscan/Isaac). These address aging demographics through efficiency gains in screening, precision medicine, and robotics. Taiwan Major medical centers (NHRI, Chang Gung Memorial Hospital/CGMH, National Taiwan University Hospital/NTUH, Taichung Veterans General Hospital/TCVGH, Kaohsiung Medical University Hospital, and others) extensively deploy NVIDIA hardware (DGX, H100/H200/B300, Jetson, Holoscan/IGX) and software (MONAI, Omniverse) for biomedical research, imaging, and smart hospitals. Collaboration often involves local system builders (Foxconn, Advantech, etc.). blogs.nvidia.com Cancer AI examples: Liver cancer detection (ultrasound AI at NTUH). Pancreatic cancer from CT scans (NTUH using DGX). Breast cancer early detection and 3D virtual models (Foxconn AI with Hopper/DGX/MONAI). Colorectal/colonoscopy lesion detection. Intraoperative lymph node metastasis diagnosis during cancer surgery (rapid AI pathology pipeline using MONAI/CUDA; National Taiwan University collaboration). Broader: genomic analysis, multimodal imaging, and clinical decision support. Digital twins appear in hospital environments (e.g., Foxconn/Omniverse digital twins of wards/nursing stations for robot training and planning at TCVGH and others) and patient/surgical simulation (e.g., NTUH XR-based digital twin patients for pre-op planning). There is also an AI Digital Twin Lab at National Taiwan University of Science and Technology (with NVIDIA and ASUS), focused on manufacturing/cities/medical applications for talent development—not a medical college twin program. blogs.nvidia.com Talent programs exist (e.g., NTU Smart Medicine & Health Informatics master’s with NVIDIA support). Hong Kong Cancer AI work includes: AI-driven blood analysis/early detection (building on prenatal testing tech; nasopharyngeal and broader cancer screening). PolyU’s AI Virtual Patient Simulation System: patient-centric digital twin integrating genomic, imaging, and clinical data to track cancer progression in real time and predict treatment responses (e.g., immunotherapy for non-small cell lung cancer). news-medical.net Other digital twin research (e.g., explainable twins for safer immunotherapy in liver cancer at HKU). NVIDIA has academic/research ties in the region (e.g., joint events/symposiums), but cancer AI here is less heavily framed around NVIDIA hardware partnerships compared with Japan/Taiwan. PolyU is exploring a new medical school with AI emphasis and international clinical collaborations (e.g., with Peking Union), but nothing indicates a “twin” structure with Taiwan medical colleges driven by NVIDIA. On “twin design of medical colleges out of Hong Kong and Taiwan” Searches turned up no specific twin medical college design/project linking Hong Kong and Taiwan in which NVIDIA (or cancer AI) is described as a key element. Digital twin technology is used in the region for: Patient-level models (cancer treatment simulation in Hong Kong). Surgical planning and hospital facility simulation (Taiwan, often with NVIDIA Omniverse). Training labs (Taiwan tech universities). These are independent applications rather than a coordinated “twin medical colleges” initiative between the two places. Summary: NVIDIA is deeply involved in Japan’s aging-focused healthcare AI (including multiple cancer imaging/genomics/drug efforts) and Taiwan’s hospital-level cancer diagnostics and smart systems. Hong Kong has strong independent cancer digital-twin work. No evidence supports NVIDIA as central to a twin medical college design spanning Hong Kong and Taiwan. Activity is more hospital/research institute and platform-driven than philanthropy or college twinning. Explore PolyU digital twin cancer research Investigate NVIDIA Holoscan surgical robotics tein medical college launched when jensen presented hkust eith friend harry shum. region also worth lookink collaborationss softbank and li ka shing. also eonder about uae Thought for 33s HKUST’s new (third) medical school in Hong Kong is the closest match to the “twin medical college” idea in prior discussion. It is tech- and AI-oriented, and Jensen Huang commented on it during a public appearance with Harry Shum, but it was not formally launched at that event. Jensen Huang + Harry Shum at HKUST (November 2024) On 23 November 2024, Jensen Huang received an honorary Doctor of Engineering from HKUST. He then held a fireside chat with Prof. Harry Shum (HKUST Council Chairman and longtime AI researcher, formerly of Microsoft). en.tmtpost.com During the discussion: Shum raised HKUST’s plans (and submitted proposal interest) for Hong Kong’s third medical school, noting the government decision to create one and HKUST’s early positioning. Huang advised leveraging HKUST’s core strengths in technology, computer science, and AI. He highlighted the opportunity to build a hospital/medical school “from the tech side” (AI/computer science domain expertise first) rather than the traditional model of starting as a hospital and later inserting technology—which often meets skepticism. He also discussed digital twins of human biology and AI for science as relevant frontiers. youtube.com Huang later supported HKUST more broadly (e.g., matching donations via the Jen-Hsun & Lori Huang Foundation for engineering scholars awards, linked to signed jackets from the event). This was input and encouragement during the planning phase, not the formal launch. HKUST School of Medicine timeline HKUST submitted its formal proposal in March 2025. Hong Kong government approval came on 18 November 2025 (HKUST selected over other applicants for its clear strategic positioning combining medicine with R&D/tech, global vision, and financial plan). hkust.edu.hk Groundbreaking for the interim Medical Education and Research Complex (on the Clear Water Bay campus) occurred in April 2026. First cohort (about 50 students in a four-year graduate-entry MBBS) targeted for the 2028/29 academic year. Permanent campus + integrated teaching hospital planned for Ngau Tam Mei in the Northern Metropolis. Explicit focus: integrating AI, data science, digital health, and technology with clinical training to produce tech-savvy doctors. This aligns with Huang’s comments and the region’s broader AI-for-health push (including digital twins and cancer-related AI noted previously). It is Hong Kong’s third medical school (alongside the University of Hong Kong and Chinese University of Hong Kong), designed with a distinctive tech orientation rather than a literal “twin” of a Taiwan institution. SoftBank and Li Ka-shing collaborations (region) Li Ka-shing (via Li Ka Shing Foundation and related entities) is active in Hong Kong cancer care and AI diagnostics: Donated histotripsy systems (non-invasive ultrasound tumor disruption) to Hong Kong’s medical schools/universities and affiliated hospitals (including CUHK and HKU); expanded patient subsidies for the treatment. Backed Pharus Diagnostics (Taiwan-based AI-powered cancer tests, e.g., lung and pancreatic risk screening using microRNA biomarkers), which has raised funds in Hong Kong and eyes mainland access. scmp.com SoftBank: Strong NVIDIA collaborations exist (especially in Japan on AI-native networks, physical AI, robotics, and telecom models), but public results show limited direct SoftBank–NVIDIA medical/cancer initiatives specifically tied to Hong Kong or Taiwan medical colleges. SoftBank’s broader Asia tech investments exist, but the medical AI links in this region are stronger via Li Ka-shing philanthropy and local hospital/NVIDIA partnerships (as previously covered for Taiwan/Japan). UAE The UAE is actively building AI healthcare and cancer capabilities, often with sovereign compute emphasis: AI-driven drug discovery (e.g., potential cancer treatments developed in under a year using advanced models). Prostate cancer AI diagnostics (M42/National Reference Laboratory partnership with Qritive for digital pathology). Population-level AI risk prediction for cancer, diabetes, and other diseases across Abu Dhabi hospitals/clinics. University research (e.g., MBZUAI for Alzheimer’s prediction tools; NYU Abu Dhabi for smart molecules that detect and treat cancer). Large NVIDIA GPU deployments (Blackwell/Vera Rubin systems) for AI sovereignty, with explicit attention to sensitive data domains including healthcare. Broader regional genome/AI partnerships involving NVIDIA (e.g., with Middle East institutions), plus local cancer innovation summits and early-detection tools. These are more infrastructure- and application-focused than a medical college twin project, but they parallel the Asia emphasis on AI for precision oncology, imaging, and drug discovery. In short, the Huang–Shum HKUST discussion provided high-profile advice that fits the eventual tech-forward design of Hong Kong’s third medical school (approved 2025, infrastructure underway 2026). Li Ka-shing is a notable local cancer/AI backer; SoftBank–NVIDIA ties are stronger outside pure medical colleges; and the UAE is a parallel high-activity zone for NVIDIA-enabled healthcare AI, including cancer applications. No single “twin medical college” launch event ties all these elements together at the 2024 HKUST presentation. Explore HKUST medical school AI curriculum Investigate Li Ka-shing cancer research grants Clarify HKUST medical school launch timeline Investigate Li Ka-shing cancer research grants Thought for 8s The Li Ka Shing Foundation (LKSF), established by Hong Kong philanthropist Li Ka-shing, has a long history of substantial support for cancer research, treatment technologies, clinical trials, patient subsidies, and related biomedical infrastructure. Funding often focuses on innovative therapies (especially non-invasive ones), early detection/precision oncology, and institutions in Hong Kong, Asia, and select global partners. It combines equipment donations, research grants, facility upgrades, and direct patient aid rather than a single competitive “grants program.” en.wikipedia.org Major Recent Focus: Histotripsy Technology (Non-Invasive Ultrasound Tumor Treatment) This has been a flagship area since ~2024: Donated Histotripsy systems (valued around US$3 million each) to Hong Kong’s two medical schools (University of Hong Kong Li Ka Shing Faculty of Medicine and Chinese University of Hong Kong Faculty of Medicine / CU Medicine) and Hong Kong Sanatorium & Hospital. These were among the first in Asia (including a 2.0 system). Support included training for clinicians. med.hku.hk Sponsored initial patients for clinical use/trials (e.g., 10–20+ in early phases for liver tumors; expanded support). In 2025–2026: Expanded “Love Can Help” subsidies so ~200 eligible liver cancer patients over three years can access treatment at a reduced cost (HK$50,000 instead of ~HK$260,000) via partner private hospitals. scmp.com 2025: Joint S$12 million commitment with Singapore’s Temasek Trust for two systems (to National Cancer Centre Singapore and National University Cancer Institute, Singapore) + clinical trials for liver, kidney, and pancreatic cancers. Structured via a donor-advised fund to attract further capital for regional cancer research. temasektrust.org.sg Also donated systems to the University of Cambridge and Stanford University. This emphasizes accessible, innovative cancer treatment and clinical research. Other Notable Cancer Research Grants and Donations University of Cambridge (UK): Long-term partnership. Early gifts (2002 onward) supported the Hutchison Building and Li Ka Shing Centre (home to the Cancer Research UK Cambridge Institute). In 2024, a landmark £11 million donation for the Early Cancer Institute (UK’s only facility dedicated to early cancer research); the building was renamed the Li Ka Shing Early Cancer Institute. Also endowed the Li Ka Shing Chair of Oncology. philanthropy.cam.ac.uk University of Melbourne (Australia): US$3 million (2017) to the University of Melbourne Centre for Cancer Research for precision oncology, focusing on genome-directed medicine for upper gastrointestinal tumors in the Asia-Pacific region. lksf.org University of Sydney (Australia): A$4.5 million (2018) for Australia’s first clinical trial of CAR T-cell immunotherapy in advanced pancreatic cancer (via the Li Ka Shing Cell and Gene Therapy Research Program). en.wikipedia.org University of Michigan (USA): US$4 million (2024) to establish a Research Professorship in Hepatology and cancer research funds (linked to histotripsy inventor connections). en.wikipedia.org Hong Kong institutions: Li Ka Shing Institute of Health Sciences at CUHK (established with earlier support; HK$30 million in 2021 for research space, facilities, and animal labs expansion—supports translational work including early cancer detection). cpr.cuhk.edu.hk HK$150 million (2022) to CUHK for a biomedical technology development fund (matched to ~HK$300 million total) supporting novel diagnostics/therapeutics, with cancer relevance. HK$4 million (2022/2023) for obstructive sleep apnea and lung cancer diagnosis research at HKU. Earlier TrueBeam radiotherapy systems (e.g., ~HK$40 million for Prince of Wales Hospital / CUHK). Patient subsidies and smaller grants (e.g., paediatric proton therapy, cancer patient allowances). Broader context: LKSF has given tens to hundreds of millions of HKD overall to Hong Kong medical faculties for biomedical/AI-related research (e.g., 2020 gifts totaling HK$170 million across universities including medical/biological areas). It also backed AI-powered cancer diagnostics (e.g., investor ties to Pharus Diagnostics for blood-based tests). Patterns and Approach Emphasis on translational impact: Equipment + trials + patient access in Hong Kong/Asia, plus research capacity at leading global centers. Strong ties to Hong Kong universities (especially CUHK and HKU, where Li has named institutes/professorships) and selective international partners (Cambridge, Michigan, Australian centers). Often structured as large, targeted gifts rather than open competitive grants; many support innovation that can scale regionally (e.g., early detection, precision/immuno-oncology, non-invasive ablation). The foundation’s healthcare work is part of wider philanthropy (education, medical subsidies via “Love Can Help,” etc.), with cancer as a recurring priority due to its burden in aging Asian populations. Public details come primarily from foundation announcements, university press releases, and news coverage. Full historical grant lists are not exhaustively published in one place (as is common for private foundations), but the above covers the major documented cancer-related commitments from the 2000s through 2026. For the most current specifics, the Li Ka Shing Foundation website (lksf.org) or recipient institutions are the primary sources. Explore histotripsy clinical trial results Investigate Li Ka Shing medical education grants japan nhk medicsl frintiers civers many non drug sppriaches to health smong elderly. anything relevant cancer elderly Thought for 7s Yes — NHK’s Medical Frontiers (メディカルフロンティア / NHK WORLD-JAPAN version) has covered non-drug approaches relevant to cancer in the elderly, aligning with its frequent focus on lifestyle, exercise, nutrition, and quality-of-life strategies for aging populations in Japan. Most Directly Relevant Episode “Exercise Is the Key to Surviving Cancer” (aired around early 2025; available on NHK WORLD-JAPAN and YouTube). youtube.com Key points from the episode (strongly oriented toward older patients): Regular exercise after a cancer diagnosis reduces muscle loss (sarcopenia), improves post-surgical recovery, lowers recurrence risk, and raises survival rates. Japanese research (including from the National Cancer Center Hospital East) showed that patients with greater skeletal muscle loss around the time of pre-surgery chemotherapy had much higher rates of complications such as pneumonia (35% vs. 9% in those with minor loss). Survey of elderly cancer patients undergoing rehabilitation: Their top priority was maintaining functional independence and quality of life (being able to eat, move, walk, and manage daily needs on their own) rather than simply extending lifespan. Japanese Breast Cancer Society guidelines cited: Women who exercised regularly after breast cancer diagnosis had roughly 37% lower risk of dying from the disease. Emphasis that establishing an exercise habit is “just as important as medication” at every stage (pre-treatment, during treatment, and for survivors). Practical tips included exercises for preventing breast cancer recurrence. Broader context: Japan’s 5-year cancer survival rate has reached ~65%, so patients (many elderly) are living longer with the disease, making non-drug supportive care critical. This fits the program’s pattern of highlighting accessible, non-pharmacological strategies suited to Japan’s aging society. Other Related Coverage on the Program Episodes on proton beam therapy (precise targeting that better preserves quality of life by reducing damage to healthy tissue — useful for older patients who may not tolerate conventional radiation well). Nuclear medicine / targeted internal radiation approaches for difficult or metastatic cancers. Ultrasound-based methods for destroying pancreatic cancer. Nutrition and traditional Japanese foods (e.g., natto linked by Japan’s National Cancer Center to lower mortality risk; vitamin D connections to cancer). Broader aging-related episodes (e.g., on senescent cells / “aging treatment frontiers,” lifestyle factors for longevity) that intersect with cancer risk and resilience in the elderly, since aging itself is a major cancer driver. The series routinely explores Japanese innovations in early detection, precision approaches, rehabilitation, diet, exercise, and complementary methods alongside (or instead of relying solely on) drugs. Non-drug themes for elderly health — physical activity, nutrition, functional preservation, and quality-of-life support — appear frequently and extend naturally to cancer care, given that the majority of new cancer diagnoses in Japan occur in people aged 65+. Episodes are available on the NHK WORLD-JAPAN website/app (with English versions) and often on YouTube. Search for the specific titles above for full viewing. Japanese research consistently supports exercise and multimodal lifestyle interventions as safe, low-cost ways to improve outcomes and functional status in older cancer patients. Find specific exercise protocols Explore Japanese cancer nutrition
No comments:
Post a Comment